This is not a trial meant to determine ststistical significance. It is to determine trial outcomes, where they best improve long hauler symptoms, along with markers that are effected by it.
Hence why it is “Exploratory”. Yes, personal testimony has to be taken with some grain of salt, but the negative view of this trial needs to be tempered with reality… this was Exploratory. And given the results, just with Leronlimab alone, there seems to be great benefit for Leronlimab, and even more so if combined with other treatments. But the mere fact that reported benefits we made with Leronlimab alone is very encouraging. I’m not expecting the stock to rocket with this news, but to dismiss the positives knowing it was merely exploratory is also clinically short-sighted.
I wish the best for your daughter in regards to long covid. It was uncertain in your post… was she in this specific trial?
Market Data 
Markets 
AI
